Refractory cytopenia of childhood is the most common type of childhood myelodysplastic syndrome. Because the majority of children with refractory cytopenia have a normal karyotype and a hypocellular bone marrow, differentiating refractory cytopenia from the immune-mediated bone marrow failure syndrome (very) severe aplastic anemia can be challenging. Flow cytometric immunophenotyping of bone marrow has been shown to be a valuable diagnostic tool in differentiating myelodysplastic syndrome from non-clonal cytopenias in adults.
Introduction
Myelodysplastic syndrome (MDS) in childhood is rare and has an annual incidence of 0.8 to 1.8 per million children aged 0 to 14 years. [1] [2] [3] Refractory cytopenia of childhood (RCC), defined as myelodysplasia without an increased blast count, is the most common variant of pediatric MDS. Based on the 2008 WHO criteria, 4 a distinction is made between RCC and the immune mediated bone marrow (BM) failure syndrome (very) severe aplastic anemia ((v)SAA), with presence or absence of patchy erythropoiesis, respectively, as main differentiating parameter. 5 Nonetheless, because the majority of children with RCC have a normal karyotype and 80% of patients have a hypocellular BM, differentiating RCC from (v)SAA can be challenging. 4, 6 Similar challenges are encountered in distinguishing (v)SAA and other non-clonal cytopenias from low-grade MDS in adults, especially in cases without specific morphologic or cytogenetic aberrations. Flow cytometric immunophenotyping is a valuable addition to morphology in the diagnosis of MDS in adults. 7 Abnormalities detected by flow cytometry in myelomonocytic, erythroid and/or myeloid blast cells [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] can be of diagnostic and prognostic relevance in adult MDS. [18] [19] [20] In pediatric MDS, only a limited number of flow cytometric immunophenotyping studies have been reported. In advanced pediatric MDS, CD7 expression on myeloid blast cells was described to correlate with dismal survival. 21 We recently showed that in RCC, a simple and reproducible flow cytometric scoring system, described by Ogata and others as diagnostic tool in adult low-grade MDS, 15, 17 cannot be applied due to a low sensitivity.
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In the present study, we performed a comprehensive flow cytometric analysis of the maturing granulocytic, monocytic, and erythroid lineages in BM aspirates of 81 RCC patients, collected prospectively by the European Working Group of MDS in Childhood (EWOG-MDS), and in BM aspirates of healthy controls, advanced MDS and (v)SAA patients. Our aims were threefold. First, to describe the immunophenotypic characteristics of RCC compared to healthy and pathologic controls. Second, to correlate flow cytometric findings with clinical characteristics of RCC patients. And third, to assess whether flow cytometry can be of value in differentiating RCC from (v)SAA.
Methods

Patients and controls
BM samples for flow cytometric immunophenotyping were obtained from 81 primary RCC patients RCC was diagnosed according to WHO criteria 4 and confirmed by central review of bone marrow morphology and histology in participating national study centers by reference pathologists of EWOG-MDS. BM samples obtained from 17 pediatric (v)SAA patients (median age: 9.6 years; range: 1.6-18.1 years), 7 pediatric patient with advanced MDS (refractory anemia with excess blasts (RAEB) or refractory anemia with excess blasts in transformation (RAEB-t) (median age: 14.3, range: 3.9-17.7 years), diagnosed according to WHO criteria 4 by reference pathologists of EWOG-MDS, and 9 healthy adult stem cell donors served as controls. The histopathological differentiation between RCC and (v)SAA is mainly based presence of patchy erythropoiesis with defective maturation and/or the presence of micromegakaryocytes in RCC, and the absence of erythropoiesis and megakaryopoiesis in (v)SAA. 5 It was recently shown that a reproducible distinction between RCC and (v)SAA can be made based on these criteria. 5 In the RCC cohort, PNH clones and T-cell receptor Vβ skewing were detected as described previously. were present, percentages were reported, but cell populations were not further characterized.
The total number of flow cytometric abnormalities was calculated by adding up all flow cytometric abnormalities described in Table 1 .
Statistical analyses
Statistical analyses are described in Supplemental Methods.
Results
Patient characteristics
A total of 81 treatment-naïve RCC patients (40 male, 41 female), with a median age at diagnosis of 10.5 years (range: 1-18 years), were analyzed. Median time from diagnosis to analysis was 1.5 months. Clinical characteristics of the included patients are summarized in Table 3 and Figure 1 . In Supplemental Figure 2 , the bone marrow cellular composition of RCC patients and controls is depicted graphically.
Immunophenotype of myeloid blast cells in RCC and controls
In adult MDS patients, the granularity of myeloid blast cells is frequently decreased, and lineage infidelity markers are often detected. 19 In our RCC series, the granularity of myeloid blast cells (CD117 Table 4) .
Immunophenotype of erythroid cells in RCC and controls
The most frequently observed abnormality in immature erythroid cells in RCC was heterogeneous expression of CD71 (transferrin receptor) and CD36 (thrombospondin receptor), which was detected in 42 of 72 RCC patients (58%) with evaluable erythroid cells (Figure 2A-C) . In healthy controls, one patient showed heterogeneous expression of CD36; 2 of 11 evaluable (v)SAA patients (18%) and 3 of 7 RAEB(-t) patients (43%) showed heterogeneous expression of CD36 and CD71 ( Table 4 ). In the RCC, (v)SAA, and RAEB(-t) patients with heterogeneous expression of CD71 and CD36, this always co-occurred.
Immunophenotype of granulocytes in RCC and controls
No differences in the relative SSC of granulocytes (CD33 Table 4 .
Immunophenotype of monocytes in RCC and controls
The relative SSC of monocytes (CD64 in RCC patients and controls, including RAEB(-t), are described in Table 4 .
Total number of flow cytometric abnormalities in RCC compared to controls
Of the 81 RCC patients, 57 (70%) displayed one or more flow cytometric abnormalities, and 49 (60%) two or more. In 1 healthy control BM sample, flow cytometric abnormalities were present. This control sample displayed a decreased granularity of the monocytes, and heterogeneous expression of CD71 on immature erythroid cells. Of the (v)SAA patients, 6 of 17 (35%) had one or more, and 2 of 17 (12%) had two or more abnormalities. In the RAEB(-t) group, all patients displayed two or more abnormalities. Using a cutoff of 2 abnormalities, flow cytometry has a sensitivity for the recognition of RCC of 60%, and a specificity, using (v)SAA patients as control group, of 88%.
The median number of abnormalities was 2 (range, 0-6) in the RCC patients, which is higher than the number of abnormalities in healthy control BM (median, 0; range 0-2, P=0.0018), and higher than in the (v)SAA patients (median, 0; range, 0-3; P=0.0012), but lower than in RAEB(-t) patients (median, 4; range, 2-9;
P=0.0017) (Figure 3 ).
Of interest, one patient with MDS-RAEB had no detectable CD34 + B-cell precursors, very few 
Flow cytometric abnormalities and clinical characteristics in RCC
No significant associations were detected between the presence of flow cytometric abnormalities (defined as two or more abnormalities) in RCC patients and age or sex, the presence of human leukocyte antigen (HLA)-DR15
(found in an increased frequency in adult low-grade MDS and aplastic anemia patients 32,33 and associated with a better response to IST 34 ), BM cellularity, transfusion dependency at diagnosis, the presence of a PNH clone, or skewing of the T-cell receptor Vβ chain (data not shown). Of interest, however, all 5 RCC patients carrying the cytogenetic abnormality monosomy 7, associated with a high risk of progression to AML, all had at least two immunophenotypic abnormalities. Heterogeneous expression of CD71 and CD36 on erythroid cells, also the most frequently occurring abnormality in the total RCC cohort, was present in 4 of 5 patients carrying monosomy 7; the other abnormalities were non-recurrent or recurrent in only 2 of 5 patients (Supplemental Table 2 ). No relation was detected between the presence of flow cytometric abnormalities and white blood cell count, absolute neutrophil count, hemoglobin level, MCV, or thrombocyte count (data not shown). Only 22 RCC patients with a hypocellular bone marrow included in this study were treated with IST. In this limited number of patients, no significant association was observed between the presence of flow cytometric abnormalities and IST response (data not shown).
Combination of cytopenia and flow cytometric abnormalities to identify RCC and (v)SAA patients
In the majority of RCC patients, immature myeloid and/or lymphoid cells were reduced in numbers, but still detectable, while in the vast majority of (v)SAA patients, myeloid blast cells and CD34 + B-cell precursors were absent: both cell types were absent in 27 of 81 RCC patients (33%) and in 15 of 17 (v)SAA patients (88%). Two or more immunophenotypic abnormalities were detected in 49 of 81 RCC patients (60%), and in 2 of 17 (v)SAA patients (12%). If a diagnosis of RCC was considered if myeloid blast cells and/or CD34+ B-cell precursors were present, or if two or more immunophenotypic abnormalities were detected, 61 of 81 RCC patients (84%) could be correctly classified, whereas the specificity of this combination, using (v)SAA as a control group, was 76% (13 of 17 (v)SAA patients) (using conventional diagnostics including histopathology as the gold standard). The positive and negative predictive values were 94% (68 of 72 patients) and 50% (13 of 26 patients), respectively.
In 55 RCC patients with a hypocellular BM, and a normal karyotype or insufficient metaphases to obtain a karyotype, 45 patients were correctly identified by flow cytometry as RCC, resulting in a sensitivity of the combined score in this group of patients of 82%.
Discussion
Flow cytometric immunophenotyping has been shown to be of value in distinguishing MDS from non-clonal cytopenias in adult patients. 7 In the present study, we evaluated whether flow cytometry can aid in distinguishing RCC from healthy controls, and from (v)SAA and advanced MDS. We analyzed percentages and/or dysplastic features of the immature myeloid and lymphoid, immature erythroid, maturing granulocytic, monocytic and lymphocyte compartments.
In RCC the myeloid compartment, both mature and immature, appeared severely compromised in comparison to healthy controls. This finding is not unexpected, because BM is hypocellular in the majority of was also not observed frequently in RCC. In adult MDS, lineage infidelity marker expression correlates with an increased blast percentage, and a more advanced disease stage. 19, 37 That RCC is a low grade MDS subtype may partly explain the low frequency of lineage infidelity marker expression on myeloid blast cells. In RCC, the most frequently occurring immunophenotypic abnormality was heterogeneous expression of CD71 and CD36 on erythrocytes in 58% of cases (discussed below), followed by aberrant expression of CD56 on monocytes in 20% of cases, which might reflect stressed hematopoiesis rather than true dysplasia. All other abnormalities occurred in a lower frequency in RCC.
Of interest, although only 5 patients with monosomy 7 were included in the present study, all of them displayed at least 2 flow cytometric abnormalities. RCC with monosomy 7 confers a high risk of progression to AML, but histopathologically, no differences can be detected between RCC cases with or without monosomy 7. The rate of clonal evolution after IST in RCC patients, ranging from 4% to 14% (in rabbit and horse ATG, respectively), 42 might be higher than in (v)SAA patients, in whom the probability of clonal evolution had dropped to 3% in a recent interim analysis (type of ATG not reported). 5 Furthermore, while the conditioning regimen before hematopoietic stem cell transplantation is myeloablative (reduced intensity in selected patients) in RCC, this is not the case in (v)SAA patients.
43,44
One of the limitations of this study is the possibility of peripheral blood contamination of bone marrow aspirates. Future studies might choose to determine the purity of bone marrow or to correct for peripheral blood contamination by methods that have been described previously. 45-47 A certain degree of peripheral blood contamination seems unavoidable, given the hypocellularity of bone marrow in the majority of RCC patients.
Another limitation of our study and of most other studies evaluating the value of flow cytometry as diagnostic tool in MDS, is that, although determining cell numbers by flow cytometry is fairly objective, scoring of dysplasia remains subjective. Therefore, future studies assessing the value of flow cytometry as a means to differentiate RCC from non-clonal cytopenias should employ more standardized protocols and antibody panels, and novel software tools that might be able to more objectively evaluate myeloid dysplasia. 
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Westers TM, Alhan C, Chamuleau ME, van der Vorst MJ, Eeltink C, Ossenkoppele GJ, et al. 2 When both granulocytes and monocytes had a decreased expression of CD33, this was not considered abnormal. 3 No data available in one RCC patient. 4 In one RCC patient, a PNH clone in the granulocytic lineage of 86% was present; no data available in another RCC patient. 5 In one RCC patient, insufficient monocytes for reliable analysis were present in this labeling; no data available in one RCC patient. In 2 RAEB patients, monocytes could not be reliably gated based on SSC and CD45 expression. NBM, normal bone marrow. 
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Supplemental Methods
Patients and controls
Data were reported to the coordinating study center of the EWOG-MDS study group through standardized data collection forms. Patients were HLA-typed for human leukocyte antigen (HLA)-A, -B, -C, -DR and -DQ by serological or molecular methods in the participating study centers. RCC patients included for analysis were either followed with a watch-and-wait strategy (n=17), or were treated with immunosuppressive therapy (IST) (n=24, of which n=22 with a hypocellular bone marrow), or received a hematopoietic stem cell transplantation (HSCT) (n=39; in n=1 no information on treatment was available), based on a treatment algorithm according to EWOG-MDS RC06 as previously described. 1 Details on treatment with IST and treatment response have been described previously.
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Gating strategies and cell population definitions
After exclusion of debris and dead cells based on scatter and CD45 expression, cell populations were identified using CD45 expression and forward or sideward scatter (FSC/SSC) properties, and additional markers when indicated. Granulocytes were defined as CD45 
Statistical analyses
Statistical analyses were performed with SPSS 20 (IBM, Chicago, IL, USA) and GraphPad Prism 6
(GraphPad Software, Inc., La Jolla, CA, USA). Categorical variables were compared using the Chi-square test or Fisher's exact test. Continuous variables were compared using the Mann-Whitney-U test or the Kruskal-Wallis test when more than two groups were compared. All reported P-values are two-sided and were considered statistically significant when <0.05; P-values >0.1 were reported as non-significant (NS), whereas those between 0.05 and 0.1 were reported in detail.
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